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ABSTRACT
Introduction: Ropivacaine is a local anesthetic
widely used for regional anesthesia. One of its
advantages is low toxicity at plasma
concentrations reached systemically during
continuous peripheral or central nervous block.
The objective of this study was to test the effect of
systemic ropivacaine on pain, hyperalgesia,
dynamic allodynia, and flare response.
Methods: This randomized, double-blinded,
placebo-controlled, crossover study was carried
out in at the Clinical Trials Centre, University of
Zurich, Switzerland. Twenty healthy male
volunteers were included in the study.
Exclusion criteria were contraindications
or hypersensitivity to local anesthetics,
vulnerable subjects (intellectually or mental
impaired), drug, alcohol or nicotine abuse,
known peripheral neuropathies, diabetes
mellitus and/or congestive heart disease.
Ropivacaine and saline were infused
intravenously during a subcutaneous electrical
stimulation. The stimulation software adjusted
the stimulus strength according to the rating on
a numeric rating scale (NRS; 0–10) maintaining
a NRS of 5. Areas of punctate hyperalgesia,
dynamic allodynia, and flare response were
measured before and after the infusion.
Results: The area of hyperalgesia increased
significantly with saline (303 ± 380%, P\0.05)
and ropivacaine (186 ± 137%, P\0.05). The
area of allodynia (253 ± 299%, P\0.05) and
flare response (112 ± 24%, P\0.05) increased
only during the placebo infusion.
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version of this article (doi:10.1007/s40122-013-0021-z)
contains supplementary material, which is available to
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Conclusion: The results of this study imply that
systemic ropivacaine may diminish pain
sensitization processes.
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sensitization; Ropivacaine
INTRODUCTION
Local anesthetics play an important role in
perioperative analgesia. By means of continuous
peripheral or central nerve blocks, they can
easily be effective for days with the appropriate
management and a minimal risk of toxic effects
[1, 2]. Although the plasma concentrations
measured after several days of continuous
infusion increase considerably, they remain
low enough to be tolerated [3].
A whole body of evidence suggests that not
only do local anesthetics prevent the
transmission of action potentials at high
concentrations (local effect), but also they
can modulate pain pathways at low plasma
concentrations (systemic effect) [4, 5]. This
modulation involves direct interaction of the
local anesthetic with neuronal tissue [6–8] as
well as indirect mechanisms via a reduction of
circulating pro-inflammatory cytokines
[9, 10].
The pure S-enantiomer ropivacaine is
widely used in clinical practice for its safety
profile [11, 12] and the lowest potential for
neurotoxicity [13]. Recently published data
on the effect of low-dose ropivacaine on
mechanisms of peripheral neurogenic
inflammation concluded that ropivacaine may
be useful in the suppression of inflammation,
mechanical and visceral hypersensitivity [14,
15]. Some authors even consider ropivacaine to
be a promising alternative to systemic lidocaine
which is used to treat chronic pain states [16].
The aim of our study was to quantify the
effect of low-dose ropivacaine on hyperalgesia,
allodynia, and flare reaction in a model of
electrically induced pain in healthy volunteers.
This model allows the study of acute and
secondary pain phenomenon evoked by
electrical current administered on peripheral
nerve endings in the skin. It has been used in
earlier investigations to show that local
anesthetics can prevent the development of
these symptoms [7, 17]. The information
gained from this study might be important to
evaluate the contribution of systemic
ropivacaine in the analgesic/anti-hyperalgesic
effect of continuous perineural blocks in clinical
practice.
METHODS
Subjects and Study Design
The experimental protocol was approved
by the Kantonale Ethikkommission Zu¨rich,
Sonneggstrasse 12, 8091 Zu¨rich, Switzerland,
registration nr. StV. 24-2008, Chairperson Prof.
R. Maurer on April 21, 2009 and the Swiss
regulatory authorities (Swissmedic, 2009 DR
4027). The study was carried out at the Clinical
Trials Centre of the University Hospital of Zurich
in accordance with the Helsinki Declaration
of 1975, as revised in 2000 and 2008, and
the guidelines of Good Clinical Practice
(Clinicaltrials.gov: #NCT00900913). Written
informed consent was received from all patients
before inclusion in this study. Twenty healthy
male volunteers were included in this
randomized, double-blinded, placebo-controlled,
crossover study. Inclusion criteria were male:
age 18–65 years; weight: 50–100 kg; height:
155–195 cm; signed and dated informed
consent. Exclusion criteria were
contraindications or hypersensitivity to local
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anesthetics, vulnerable subjects (intellectually or
mental impaired), drug, alcohol or nicotine
abuse, known peripheral neuropathies, diabetes
mellitus and/or congestive heart disease. All
subjects were familiarized with the tests
performed before undergoing two testing
sessions at least 1 week apart, receiving
ropivacaine and saline as a placebo.
Randomization of the sequence of the test
drugs was generated with the method of
envelopes by an un-blinded research assistance
who was not involved in the collecting or the
assessment of data.
Electrical Pain Model and ‘Pain Tracking’
An electrical hyperalgesia model was used to
induce ongoing pain, hyperalgesia, allodynia,
and flare reaction [18]: Two insulated gold wires
(AU-3T, 76 lm, Science Products GmbH,
Hofheim, Germany) diameter were inserted
1 cm intradermally into the left central volar
forearm of the subjects. The distance between
the un-insulated tips of the two gold wires was
5 mm. Electrical stimuli (rectangular; 1 ms)
were applied via a constant current stimulator
(DS5, Digitimer Ltd., Hertfordshire, UK) at 1 Hz.
The study subjects were asked to rate the pain
intensity in their arm on a box with a sliding
button on a numeric rating scale (NRS; 0: no
pain; 10: maximal pain imaginable). The box
was connected with a software (QtracW,
Institute of Neurology, London, UK) which
‘tracked’ the pain intensity and adjusted the
stimulus strength according to the rating
(Fig. 1). In the current study, we designed the
stimulation protocol in a way to inflict a pain
intensity of NRS 5. For example, if the subject
indicated on the box a pain intensity value less
than 5, the stimulation strength automatically
increased in one-percent steps. If the pain
intensity was rated more than 5, stimulation
strength automatically decreased in one-
percent steps. This stimulation approach
forced the subjects to rate the pain
continuously by means of the box, because
the stimulation current was either increasing or
decreasing.
The rationale of this setup was based on
theoretical and practical advantages. First, we
wanted to ‘optimize’ the development of
peripheral and central symptoms by
Fig. 1 Pain tracker. The experimental set-up used in this
study allowed a constant pain experience by adapting the
current strength to the actual rating (pain tracking).
Electrical pain was generated by a constant current
stimulator on the volar side of one forearm of the study
subject. On the other hand, the subjects were rating
continuously the intensity of the inﬂicted pain on a scaled
box (0 no pain, 10 maximal pain imaginable) with a sliding
button. The box was connected to computer software
(QTRAC) which adjusted the stimulator output accord-
ing to the actual rating of the study subject. If the pain
rating was below 5, stimulus strength was slowly increased.
If the pain rating was more than 5, the stimulus strength
slowly decreased. NRS numeric rating scale
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maintaining a constant intensity of the pain
stimulus over time and independent of
endogenous suppressing mechanisms which
were described with this model [19]. Second,
rating a constant pain ‘experience’ where a
study subject only has to decide if the pain
intensity is stronger or less strong than a
defined value is an easier task than using a full
numerical rating scale. As a consequence of this
‘pain tracking’, the stimulation current was
expected to increase over time. Preliminary
experiments in four pilot subjects showed that
after 20 min of stimulation in all of the subjects,
the stimulation current increased more than
40% within the subsequent 30 min (Fig. 2).
Based on this information, we designed the
study and defined two reading points (Fig. 3):
electrical stimulation was started and continued
for 20 min until t0; the current intensity to
maintain an NRS 5 at t0 was defined as 100%
and baseline sensory testing was performed (see
below). At t0, an infusion of the drug was
started (under on-going stimulation) at a
constant rate until t1, defined as the time after
t0 when the current intensity reached 140% (of
the intensity at t0). One of the endpoints of the
study was to measure a possible analgesic effect
of systemic ropivacaine on the acute local pain
sensation induced by the electrical stimulation.
If ropivacaine produced any analgesic effect—so
the hypothesis—the stimulation intensity
threshold of 140% would be reached earlier
than a placebo infusion.
Fig. 2 Current increase over time after 20 min of stim-
ulation (pilot study, n = 4). In a preliminary set of
experiments in four subjects, current increase over time at a
numeric rating scale of 5 was recorded. Between 20 and
50 min of stimulation, all of the subjects increased the
stimulation current to at least 140%. Each line represents
the normalized current increase in an individual subject
Fig. 3 Time course of experiment. After initial adaptation
to the painful stimuli, the subjects were asked to rate their
pain intensity on the pain tracking box (see Fig. 1). The
pain tracker forced the subject to maintain a pain intensity
of 5 (a). To maintain a constant pain rating level, the
current strength has to increase over time due to
endogenous pain suppressing mechanisms (b). Before
starting the drug infusion at t0, a ﬁrst sensory testing
was performed. Stimulation was restarted and the subjects
continued rating the pain. The drug was infused at a
constant rate until the current strength of the stimulation
reached 140% (t1) of the current strength deﬁned as 100%
at t0. Subsequently, the second sensory testing was
performed. iv intravenous NRS numeric rating scale
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Treatments and Dose Rationale
Administration of systemic ropivacaine is an
off-label use of the drug and associated with
risks of toxicity [20]. By defining the dosages,
particular care was taken to avoid potential
dangerous side effects. The calculation was
based on previously published data [21].
The treatment infusions were prepared by an
independent non-blinded investigator
according to the body weight of the study
subjects: Ropivacaine 1 mg/kg (Naropin
AstraZeneca AG, Zug, Switzerland), drawn up
with NaCl 0.9% to a total volume of 30 ml
volume per syringe. Using this approach, the
maximum dose infused in a study subject could
not reach any dangerous plasma levels if the
target threshold of 140% (see above) was not
reached within 30 min. The placebo infusion
consisted of 30 ml of NaCl 0.9%. 20 min after
the start of the electrical stimulation (t0), the
subjects received the treatment intravenously
delivered with an infusion pump (Alaris GH
Syringe Pump, Cardinal Health, Rolle,
Switzerland) at a rate of 60 ml/h. The infusion
of the drug was stopped as soon as the target
current of 140% was reached (t1). During the
infusion of the drug, the study subjects were
regularly checked for side effects, such as
pruritus, perioral numbness or tingling,
hypoacusis or hyperacusis, dizziness, nausea,
sedation, or dissociative effects. Pulse oximetry
(oxygen saturation), electrocardiogram, and
non-invasive arterial pressure were monitored
continuously.
Sensory Testing
At the reading points t0 and t1, the area of
punctate hyperalgesia was measured with a
256 mN von Frey filament (Fruhstorfer,
Erlangen, Germany), and the area of dynamic
allodynia was determined with a standardized
brush (Somedic, Ho¨rby, Sweden) exerting a force
of approximately 200–400 mN gently stroked on
the skin. The borders of the hyperalgesic areas
were delineated by stimulating along four linear
paths parallel and vertical to the axis of the
forearm from distant starting points toward the
stimulation site, until the study subject reported
increased pain sensations evoked by the von
Frey filament (punctate hyperalgesia) or
unpleasant sensations or pain by stroking the
skin with brush (allodynia) [18]. These sites were
marked on the skin and traced on sheet at the
end of the experiment. For further analysis, both
diameters were used to calculate the areas of
hyperalgesia.
Flare Reaction
Superficial blood flow of the stimulated arm was
measured repetitively by laser Doppler imaging
(moorFLIPI, Moor Instruments Ltd., Devon,
United Kingdom). For this purpose, an area of
16 cm by 8 cm around the injection sites was
scanned with a resolution of 49,000 pixels per
cm2, with each pixel representing a separate
Doppler flux measurement. Data were stored on
hard disk and processed offline with dedicated
software (MoorLDIVersion 5.0, Moor Instruments
Ltd.). The flare area was calculated from all pixels
around the stimulation site in which flux values
exceeded the 95% percentile of the baseline
distribution [22]. Laser Doppler images were
recorded before starting the stimulation (baseline
image), at the beginning of the infusion (t0) and at
the end of the infusion (t1).
Statistical Analysis
The hypothesis of this study was that low-dose
ropivacaine may affect clinical signs like
hyperalgesia, allodynia and flare reaction
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(primary endpoints). Secondary endpoints were
time to reach the threshold current and
incidence of side effects. To our knowledge, no
previous study has investigated these
endpoints. For our sample size determination,
we, therefore, used an approximation based on
data previously published on lidocaine [7]. We
calculated a SD of 6.9 cm2 hyperalgesia after
18-min subcutaneous electrical stimulation in a
treated and non-treated group. We supposed a
mean difference of hyperalgesia of 5.5 cm2 and
calculated a power of 90% for a sample size of
Fig. 4 Flow diagram of the progress through the phases of trial (enrollment, intervention allocation, follow-up, and data
analysis)
50 Pain Ther (2014) 3:45–58
19 subjects with a paired t test (P\0.05). All
results were expressed as mean ± SD, except for
in the figures in which data are presented as
mean ± SE. IBM SPSS StatisticsTM 19.0.1 (SPSS
Inc., Chicago, IL, USA) was used for statistical
analysis. Stimulation duration to reach t1 was
tested with paired t test assuming normal
distribution. Data of hyperalgesia, allodynia
and flare reaction at t0 and t1 were normalized
and then tested with paired t test assuming
normal distribution. Side effects were analyzed
with McNemar test.
RESULTS
All 20 subjects included in the investigation
finished the study (Fig. 4). One subject was not
able to clearly indicate hyperalgesia or allodynia
in any of the sessions and the data were not
included in the analysis. An overview of the
demographic of the study population is given in
Table 1. Maintaining a pain intensity of 5
during the stimulation time on the NRS box
was considered to be an easy task by all the
subjects and was well tolerated.
Table 1 Demographic data
Study subject
(number)
Age
(years)
Height
(cm)
Weight
(kg)
Total ropivacaine
infused (mg)
Ropivacaine
infused (mg/kg)
1 39 171 75 55.0 0.7
2 26 179 64 42.7 0.7
3a 28 170 63 16.8 0.3
4 37 179 75 35.0 0.5
5 27 189 84 22.4 0.3
6 29 180 76 17.7 0.2
7 28 186 70 9.3 0.1
8 26 179 75 60.0 0.8
9 35 183 67 58.1 0.9
10 29 172 63 31.5 0.5
11 25 174 67 38.0 0.6
12 33 171 68 29.5 0.4
13 25 190 90 57.0 0.6
14 33 178 78 62.4 0.8
15 26 172 67 17.9 0.3
16 27 175 75 17.5 0.2
17 21 184 85 65.2 0.8
18 26 177 79 71.1 0.9
19 26 186 99 46.2 0.5
20 25 183 86 63.1 0.7
Mean ± SD 30 ± 5 179 ± 6 75.3 ± 10.0 40.8 ± 19.7 0.5 ± 0.2
a Subject number 3 was excluded from the analysis
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Current Increase Between t0 and t1
In all the experiments, the targeted threshold of
140% of the stimulus strength at t0 was reached
within the infusion time of 30 min (Fig. 5). The
current strength at t0 was not different between
the two groups. There was no time difference in
increase to the target threshold between
ropivacaine (15.9 ± 7.0 min) and placebo
(19.1 ± 5.8 min; P = 0.10).
Hyperalgesia, Allodynia,
and Flare Reaction
The areas of hyperalgesia, allodynia, and flare
reaction were not different at t0 in the sessions
with placebo or ropivacaine. During the
infusions of the drugs, the area of hyperalgesia
did increase with placebo (303 ± 380%, P\0.05)
and ropivacaine (186 ± 137%, P\0.05) (Fig. 6).
The area of allodynia increased significantly
during the placebo (253 ± 299%, P\0.05)
infusion. We did not find any difference in
increase in allodynia during the ropivacaine
infusion (137 ± 132%, P = 0.22) between t0 and
t1. Similar results were found regarding the flare
response. The area and intensity of flare
increased significantly during the placebo
infusion (area: 112 ± 24%, P\0.05; intensity:
110 ± 17%, P\0.05) but not during the infusion
with ropivacaine (area: 107 ± 1%, P = 0.31;
intensity: 102 ± 21%, P = 0.19).
Side Effects
In nine subjects, we observed side effects
(dizziness and/or tingling around the mouth).
This was significantly higher than during the
placebo (n = 0, P\0.01) infusion.
DISCUSSION
In this investigation, systemic ropivacaine
diminished the development of brush-evoked
allodynia and flare response but not punctate
hyperalgesia or acute pain sensation. These
results suggest that ropivacaine had an impact
on both, peripheral and central nervous
mechanisms.
Hyperalgesia to mechanical stimuli may
develop at the site of injury (zone of primary
hyperalgesia) and in the uninjured area
surrounding an injury (zone of secondary
hyperalgesia) [23]. Primary hyperalgesia
involves a sensitization of primary sensory
afferents in the periphery which supposedly
causes local release of inflammatory mediators
[24]. In contrast, ‘secondary hyperalgesia’ is
characterized by increased pain intensity from
mechanical stimuli only [25] and is considered
to be caused by central mechanisms [26, 27]. As
a result, normally painful punctate stimuli
become even more painful (‘hyperalgesia’) and
input from normally non-painful stimuli is
perceived as painful (‘allodynia’). The latter is
Fig. 5 Time (t1) to reach threshold current: Effect on
acute pain sensation 20 min after the beginning of the
stimulation (t0), the drugs were infused intravenously. t1
was the time to reach the deﬁned current threshold of
140% of the current strength at t0. Error bars are SE.
During the infusion of ropivacaine, the threshold was
reached earlier than during the infusion with placebo;
however, this difference was not signiﬁcant. ROPI
ropivacaine
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mediated by low-threshold fibers which are
signaling the sensation of touch in normal
physiological conditions [28]. The mechanisms
are not fully understood but second-order
neurons in the central nervous system on the
level of the spinal cord play a major role in this
process [29].
Peripheral versus Central Effects
of Systemic Ropivacaine
On the level of the nerve endings and the
receptive field in the skin, local anesthetics
interfere with the activation of nociceptors
by blocking voltage-gated sodium channels.
This mechanism is mainly responsible for the
reduction in acute pain sensation; hence it
represents the typical analgesic effect of local
anesthetics in the peripheral nervous system [4].
It is dependent on the concentration of the
local anesthetic. In the current study, the
concentration reached systemically was
probably too low to show any analgesic effect
on the painful stimulation. This is in line with
previous investigations of low-dose local
anesthetics where in healthy volunteers also
acute nociception remained intact in the
presence of a limited and selective anti-
hyperalgesic effect of lidocaine [17, 30].
However, the flare reaction, a typical
peripheral symptom of the electrical
stimulation [26], was significantly modulated
Fig. 6 Areas of hyperalgesia, allodynia, ﬂare reaction, and
ﬂare intensity after the drug infusion at t1. The area of
allodynia increased signiﬁcantly with placebo but not with
ropivacaine compared to the baseline at t0 (dotted line).
Mechanical hyperalgesia increased signiﬁcantly with both,
ropivacaine and placebo. Area and intensity of ﬂare
increased signiﬁcantly with placebo but not with ropiva-
caine. Error bars are SE; *P\0.05
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by ropivacaine. Under physiological conditions,
activation of nociceptors leads to an erythema
in the surrounding of the injury, also called
‘flare’. This reaction is caused by mechano-
insensitive nociceptors (also called ‘‘silent
nociceptors’’) which trigger the release of
vasoactive neuropeptides (bradykinin,
calcitonin gene-related peptide, substance P) at
the nerve endings (‘‘neurogenic inflammation’’)
when activated. The most likely explanation for
a diminished flare response in the presence
of local anesthetics is an attenuation of a
vascular response to bradykinin and substance
P not only when applied locally, but also when
applied systemically at low-dose concentrations
[14]. Also, local anesthetics tend to cause
vasoconstriction which has to be taken into
consideration when interpreting flare response
[31]. It is postulated that the degree of
vasoconstriction depends on the stereo-
selectivity of the local anesthetic and,
therefore, S-enantiomers like ropivacaine could
have a more pronounced effect than the other
local anesthetics [32]. The current study
revealed that the flare response was
diminished by ropivacaine in terms of area
and intensity and, therefore, the results go in
line with previous investigations with different
systemic sodium channel blockers [7, 14, 17, 33].
Another possible peripheral effect we
observed was the diminished development of
allodynia. There is abundant evidence that large
myelinated fibers are involved in mediating
pain in the area of secondary hyperalgesia [34]
and allodynia [35]. Low-dose local anesthetics
can prevent flow of information (number of
action potentials) toward the central nervous
system, especially in neuropathic nerves [36]. As
a consequence, less neurotransmitter will be
released at the central endings in the spinal
cord, and nociceptive activity in the dorsal horn
will decrease [37]. This diminished activity in
the dorsal horn, in turn, will lead to a decrease
of ‘secondary hyperalgesia’ or allodynia on the
peripheral end of the nociceptors in the
surrounding tissue of the receptive field [6–8].
There are still no clear neurophysiological
investigations as to what the exact underlying
mechanisms of brush-evoked allodynia are, but
an involvement of the central nervous system is
undisputed [29]. Therefore, the results of this
study would imply that ropivacaine modulated
pain pathways also on a central level. Regarding
the impact on mechanical hyperalgesia,
Hahnenkamp et al. [38] found that S-
ropivacaine had a larger effect on the
inhibition of N-methyl-D-aspartate receptor
(also known as the NMDA receptor compared
to other local anesthetics. This inhibition would
imply an even stronger effect on secondary
hyperalgesia, hence on central mechanisms)
[38]. The results of this study, however,
showed that ropivacaine did not impair the
development of punctate hyperalgesia. Since
our sensory testing did not differentiate
between primary (peripheral mechanisms) and
secondary hyperalgesia (central mechanisms),
the diminished sensitization processes in the
periphery—indirectly illustrated by the
impaired flare response—would account solely
for an incomplete explanation of the lacking
efficacy. Our findings, however, are comparable
to a recent publication by Charlet et al. [39].
They found that systemic ropivacaine did not
prevent mechanical hyperalgesia compared to
locally applied ropivacaine without giving a
satisfying explanation of the underlying
mechanisms [39].
There is no clear hypothesis as to why
ropivacaine would act differently to other
sodium channel blockers in terms of central
mechanisms. In this study, despite observing a
reduced development of punctate hyperalgesia
compared to placebo, we assume that the
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concentrations reached intrathecally were not
high enough and/or the variance of the
electrical model to induce hyperalgesia was
too large to detect statistical significant effects.
CONCLUSION
The results of this study imply that systemic
ropivacaine may prevent pain sensitization
processes. Clinically, these effects could be
relevant since continuous application of
ropivacaine (e.g., continuous nerve block after
surgery) leads to substantially elevated systemic
plasma concentration. The incidence of side
effects was nearly 50% during the infusion with
ropivacaine at even low dosages. Therefore, the
therapeutic benefit to justify an intravenous use
of the drug to treat chronic pain states—as it
was proposed by other groups [16]—seems to be
very limited. Furthermore, the extrapolation of
results in this study with healthy volunteers on
neuropathic pain states in patients needs to be
verified in a clinical setting. Therefore, more
studies with different models of hyperalgesia
(e.g., UV model or capsaicin model) and in
patients with neuropathic pain are needed.
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